INVA
Innoviva Inc
NASDAQ · Pharmaceuticals
$21.80
+0.23 (+1.07%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 361.52M | 372.36M | 318.43M | 296.49M | 325.02M |
| Net Income | 23.57M | 21.85M | 97.42M | 100.45M | 107.69M |
| EPS | — | — | — | — | — |
| Profit Margin | 6.5% | 6.2% | 30.6% | 33.9% | 33.1% |
| Rev Growth | -2.9% | -2.9% | +17.6% | +12.4% | +2.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 320.66M | 320.66M | 626.42M | 569.66M | 644.56M |
| Total Equity | 494.32M | 494.32M | 1.02B | 1.17B | 1.19B |
| D/E Ratio | 0.65 | 0.65 | 0.61 | 0.49 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 191.26M | 187.14M | 169.91M | 161.71M | 177.91M |
| Free Cash Flow | — | — | 81.64M | 84.32M | 106.96M |